CX3CL1 and coronary artery disorder: Similarly, in a previous study fractalkine and its receptor (CX3CR1) were increased in circulation as well as in atherosclerotic plaque in coronary artery disease [27], providing a potential link between uremic toxicity and accelerated atherogenesis.